Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.
|Articles|July 13, 2020
COVID-19 Could Raise HIV, TB, Malaria Death Rates
Author(s)Grant M. Gallagher
A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.
Advertisement
The disruptions caused by the COVID-19 pandemic and its response could cause a surge in HIV, malaria, and tuberculosis (TB) deaths, according to a new modeling study published in
While concern has been raised about the relationship between these disruptions and other health priorities before, the new model focuses on where the worst impact would be felt: low- and middle-income countries. Their modeling seems to suggest that at current pace HIV, TB, and malaria deaths could increase by as much as 10%, 20%, and 36% respectively over the next 5 years due to the disruption of health services.
The models indicate that the stability of programs which address long standing infectious disease health burdens are at risk. In areas with substantial prior health care resource strains, the authors even note that years of life lost (defined as the number of years a person would have been expected to live had they not died of a particular cause) could in some cases be of similar scale to the biological impact of the pandemic itself. The COVID-19 pandemic has caused substantial disruptions by overwhelming struggling health systems, and through lockdown measures limiting routine health care activity and patient care-seeking. The demobilization of many sectors of industry has also lead to interruptions in medical supply chains.
The authors went on to explain that bolstering “access to antiretroviral therapy (ART), timely TB diagnosis and treatment, and early resumption of the distribution of long-lasting insecticide-treated nets and antimalarial treatment” could mitigate negative health impacts, according to a
For more on this story, Contagion spoke with co-lead author Professor Timothy Hallett of Imperial College London, UK. Hallett was careful to clarify that predicting the future impact of the ongoing COVID-19 pandemic is challenging, including due to ongoing uncertainty around the novel virus itself.
Advertisement
Related to this article
The guidelines issued by the Department of Health and Human Services (HHS) have been updated with recent, evidence-based consensus of The Panel for the Use of Antiretroviral Agents in Adults and Adolescents.
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Advertisement
Advertisement